XLV vs PBE: Comparing Two Healthcare ETFs for Investors
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowThe State Street Health Care Select Sector SPDR ETF (XLV) has an expense ratio of 0.08% and offers a yield of 1.6%, while the Invesco Biotechnology & Genome ETF (PBE) has a 0.58% expense ratio and a yield of 1.7%. XLV includes 60 holdings like Eli Lilly & Co (NYSE:LLY) at 16.5% and Johnson & Johnson (NYSE:JNJ) at 10.6%. In contrast, PBE holds 30 companies, with Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.2% and Biogen Inc (NASDAQ:BIIB) at 5.1%. This comparison helps investors weigh low-cost sector exposure versus targeted growth potential in biotechnology.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Biogen Inc. (BIIB)
Biogen is a biotech focused on neurological diseases.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BIIB news
- Biogen (BIIB), Vertiv, GE HealthCare Stocks Make Premarket Moves
- Biogen Stock Surges Today Amid Market Interest and Activity
- Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition
- Biogen (BIIB) Stock Upgrade Due to Pipeline Outlook
- Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
